Dual-Action Kinase Inhibitors Influence p38α MAP Kinase Dephosphorylation.

Area of Science:

• Biochemistry and Molecular Biology
• Drug Discovery and Development

Background:

• Protein phosphorylation regulates critical cellular functions and is implicated in various diseases.
• Kinases and phosphatases are key drug targets, with some inhibitors showing clinical success.
• Activation loop phosphorylation typically activates kinases, while phosphatases inactivate them by dephosphorylation.

Purpose of the Study:

• To investigate the role of activation loop conformation in kinase dephosphorylation.
• To identify novel inhibitors that modulate p38α mitogen-activated protein kinase (MAPK) activation loop conformation and dephosphorylation.

Main Methods:

• Modulation of human p38α MAPK activation loop conformation using existing kinase inhibitors.
• Assay development to measure dephosphorylation rates by the PPM serine/threonine phosphatase WIP1.
• X-ray crystallography to determine the structural basis of inhibitor-bound and unbound p38α conformations.

Main Results:

• Three inhibitors were identified that increase the rate of p38α activation loop phospho-threonine dephosphorylation by WIP1.
• These compounds act as dual-action inhibitors, blocking the kinase active site and stimulating dephosphorylation.
• X-ray structures revealed that dual-action inhibitors stabilize a flipped activation loop conformation, rendering the phospho-threonine accessible to WIP1.

Conclusions:

• The conformation of the kinase activation loop significantly influences phosphatase accessibility and dephosphorylation rates.
• Phosphatases exhibit conformational preferences for their phosphorylated targets.
• This study presents a novel strategy for designing potent and specific dual-action kinase inhibitors.